Bank of America Corp DE raised its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 76.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,719 shares of the company’s stock after purchasing an additional 32,422 shares during the quarter. Bank of America Corp DE owned 0.13% of Black Diamond Therapeutics worth $160,000 at the end of the most recent quarter. A number of other hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in shares of Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock valued at $41,000 after buying an additional 15,355 shares in the last quarter. Intech Investment Management LLC grew its stake in Black Diamond Therapeutics by 49.1% during the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock valued at $41,000 after acquiring an additional 6,340 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Black Diamond Therapeutics by 41.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock valued at $43,000 after purchasing an additional 5,932 shares during the period. Sei Investments Co. acquired a new position in shares of Black Diamond Therapeutics in the 4th quarter valued at about $49,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Black Diamond Therapeutics in the fourth quarter worth approximately $53,000. Hedge funds and other institutional investors own 95.47% of the company’s stock. BDTX has been the topic of a number of research reports. Wall Street Zen raised shares of Black Diamond Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright boosted their target price on Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, March 18th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. Finally, Stifel Nicolaus dropped their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $14.60. In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the sale, the insider now directly owns 2,733,547 shares in the company, valued at $5,658,442.29. This represents a 67.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.97% of the stock is owned by insiders. Shares of BDTX opened at $2.31 on Monday. The stock’s 50-day moving average price is $1.86 and its 200 day moving average price is $2.03. Black Diamond Therapeutics, Inc. has a 12-month low of $1.20 and a 12-month high of $6.75. The firm has a market capitalization of $131.35 million, a price-to-earnings ratio of -1.74 and a beta of 2.71. Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Holdings Boosted by Bank of America Corp DE

Bank of America Corp DE increased its stake in Black Diamond Therapeutics (BDTX) by 76.7% in Q4, while other hedge funds also adjusted their holdings. Research analysts raised BDTX's rating and target price, and a major shareholder sold a significant portion of shares, reducing their ownership. The company's stock has a market cap of $131.35M and is focused on oncology drug development.